MDB Direct
Community Portal
Submit Your Big Idea
Why Public Venture?
What is Public Venture?
Public Venture Advantage
How to Invest
MDB Outcomes
Why MDB?
MDB Difference
Investment Criteria
Curation Process
Outcomes
Launch Capabilities
MDB Capital Brokerage
Community
Membership Group
Member Criteria & Benefits
MDB Direct
Overview
MDB Direct
IRAs
Open an Account
Media
Videos
Press Releases
Articles
Reports
About
Overview
Our Platform
Value Creation
Join Us
Contact
Leadership Team
Submit Big Idea
MDBH Investors
Overview
Press Releases
SEC Filings
Stock Info
Governance
Email Alerts
IR Contact
Events
Select Page
National Renewable Energy Lab (NREL) working with Invizyne
by
Staff
|
Jul 26, 2024
Cue Biopharma: Leading New Revolution In Cancer Treatments
by
Staff
|
Dec 4, 2023
The Urgency Behind Biotech M&A
by
Staff
|
May 9, 2023
Resurgence of Biotech Stocks
by
Staff
|
Feb 27, 2023
Search for:
Recent Posts
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol
HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software
HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology
HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference
MDB Capital Holdings to Host Third Quarter 2024 Results Conference Call on Thursday November 21, 2024, at 4:30 p.m. Eastern Time
Recent Comments
Archives
February 2025
January 2025
December 2024
November 2024
October 2024
July 2024
May 2024
April 2024
February 2024
January 2024
November 2023
October 2023
June 2023
May 2023
November 2022
October 2022
August 2022
July 2022
June 2022
Categories
Press Releases
Uncategorized
Meta
Log in
Entries feed
Comments feed
WordPress.org
Recent Comments